title: Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer.
abstract: The anti-idiotype monoclonal antibody breast cancer vaccine 11D10 (TriAb) was administered before and after autologous stem cell transplantation (ASCT) in 45 patients with metastatic breast cancer whose disease was responsive to conventional chemotherapy. Evidence of a positive anti-anti-idiotype antibody (Ab3) humoral response was noted at a median of 1.76 months post-ASCT (range, before ASCT-6 months) with this strategy. Maximal Ab3 levels and idiotype-specific T-cell proliferative responses were observed at a median of 3 and 4 months, respectively, after ASCT. The achievement of rapid immune responses after ASCT, during a known period of decreased immunoresponsiveness, opens the possibility of an additional antitumor effect at a time when the tumor burden is relatively small. Moreover, in this interim analysis, patients with the most vigorous humoral and cellular immune responses had a significant improvement in progression-free survival. Further follow-up and evaluation of this approach is warranted.
authors.affiliation: University of Kentucky, Blood and Marrow Transplant Program, Lexington, KY, USA. dereec2@pop.uky.edu
authors.forename: D E
authors.initials: DE
authors.lastname: Reece
authors.forename: K A
authors.initials: KA
authors.lastname: Foon
authors.forename: M
authors.initials: M
authors.lastname: Battacharya-Chatterjee
authors.forename: D
authors.initials: D
authors.lastname: Adkins
authors.forename: E R
authors.initials: ER
authors.lastname: Broun
authors.forename: D G
authors.initials: DG
authors.lastname: Connaghan
authors.forename: J F
authors.initials: JF
authors.lastname: Dipersio
authors.forename: H K
authors.initials: HK
authors.lastname: Holland
authors.forename: D S
authors.initials: DS
authors.lastname: Howard
authors.forename: G A
authors.initials: GA
authors.lastname: Hale
authors.forename: H G
authors.initials: HG
authors.lastname: Klingemann
authors.forename: R K
authors.initials: RK
authors.lastname: Munn
authors.forename: A
authors.initials: A
authors.lastname: Raptis
authors.forename: G L
authors.initials: GL
authors.lastname: Phillips
mesh_terms: D000328:Adult; D000368:Aged; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D000911:Antibodies, Monoclonal; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006017:Glycolipids / Q000276:immunology*; D006023:Glycoproteins / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007111:Immunity, Cellular; D066292:Lipid Droplets; D008213:Lymphocyte Activation; D008875:Middle Aged; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D006017:Glycolipids; D006023:Glycoproteins; C110367:milk fat globule